NCT02446704View on ClinicalTrials.gov

Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 13, 2015

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2023

Conditions
Small Cell Lung Cancer
Interventions
DRUG

Olaparib

DRUG

Temozolomide

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Zofia Piotrowska

OTHER